MoonLake Immunotherapeutics Stock Wilted: Investor Guide
When MoonLake Immunotherapeutics announced a larger-than-expected secondary offering, the stock wilted. This guide br...
Biotech Stocks
Biotech Stocks page aggregates 6 articles covering catalysts, earnings moves, and company updates to help you spot opportunities and manage biotech investments more confidently.
180 articlesArcutis Director Sells $121,000 Amid ZORYVE Revenue Surge
A biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
What $350,000 Insider Sale Signals Mineralys Investors
A high-profile insider sale at Mineralys raises questions about what it might mean for the biotech's near-term trajec...
Viking Therapeutics Stock No-Brainer: Is It Worth Buying Below $35?
Viking Therapeutics trades around the low $30s as pivotal data for VK2735 approaches. This article breaks down whethe...
Zenas Biopharma's Purchased 60,000: Insider Buy Deep Dive
A biotech CEO just bought a sizable chunk of his company’s stock. That move sparks questions about conviction, risk, ...
Fresh IPO Signals: Director Buys PBLS Stock—What It Means
A Parabilis Medicines director recently disclosed a substantial stake just after the company’s fresh IPO. This articl...
Crispr Therapeutics Stock Been: A Roller-Coaster Year Unpacked
CRISPR Therapeutics stock has zigzagged all year, driven by pipeline milestones, regulatory updates, and funding need...
IShares Pharma ETF vs SPDR's Biotech: Long-Term Buy?
Investors debating IHE vs XBI face a trade-off between stability and growth. This guide breaks down how ishares pharm...
This Stock This Year: Is It Still a Buy or Too Late?
A stock rising 58% this year can signal momentum or a looming reversal. This guide helps you evaluate whether it rema...
Ligand Pharmaceuticals Director Unloads: Investor Guide
A director sold a chunk of Ligand Pharmaceuticals stock, prompting questions about intent and impact. This guide brea...
Reasons Lilly Stock Like There’s No Tomorrow: A Bold Buy
Seeking a stock with growth, resilience, and optionality? This article lays out three strong reasons to consider Lill...
What Does Bicara Therapeutics CEO Sale Signal Investors
When a biotech CEO sells shares after exercising options, investors rightly pause to interpret the move. This article...
Related Topics
#Investing (146)
#Stock Analysis (44)
#Earnings Analysis (28)
#Insider Trading (28)
#Stock Market (20)
#Portfolio Strategy (16)
#Stock Market News (16)
#Earnings (14)
#Portfolio Management (12)
#Eli Lilly (10)
#Investing Strategy (9)
#SEC Filings (7)
#risk-management (6)
#Hedge Funds (6)
#CRISPR (6)